Back to top
more

INC Research Holdings, Inc. (SYNH)

(Delayed Data from NSDQ)

$47.27 USD

47.27
483,054

+0.56 (1.20%)

Updated May 3, 2019 04:00 PM ET

After-Market: $47.36 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Syneos Health (SYNH) Q4 Earnings Top Estimates, Margins Down

Syneos Health (SYNH) reports better-than-expected earnings for the fourth quarter and strong performances by the Clinical Solutions and Commercial Solutions arms.

Syneos Health (SYNH) Q4 Earnings Beat Estimates

Syneos Health (SYNH) delivered earnings and revenue surprises of 3.50% and 2.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Reports Next Week: Wall Street Expects Earnings Growth

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Riya Anand headshot

4 Internet of Medical Things (IoMT) Stocks to Buy for 2022

Stocks like Boston Scientific (BSX), Medtronic (MDT), DexCom (DXCM) and Syneos Health (SYNH) are evolving rapidly in the field of IoMT.

Why Is Syneos Health (SYNH) Down 4.1% Since Last Earnings Report?

Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold on to Syneos Health (SYNH) for Now

Investors about optimistic about Syneos Health (SYNH) given its better-than-expected results as well as strong segmental performance during the third quarter.

Why Syneos Health (SYNH) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Syneos Health (SYNH) Q3 Earnings Top Estimates, 2021 EPS View Up

Syneos Health (SYNH) reports better-than-expected results for third-quarter 2021 on strength in Clinical Solutions and Commercial Solutions arms driving the top line.

Syneos Health (SYNH) Q3 Earnings and Revenues Surpass Estimates

Syneos Health (SYNH) delivered earnings and revenue surprises of 3.39% and 0.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Syneos Health's (SYNH) New Pact Boosts Tech-Driven Solutions

Syneos Health's (SYNH) recent acquisition boosts the company's ability to deliver strategic insights and technology-enabled solutions that address the customers' most complex data challenges.

Here's Why You Should Retain Syneos Health (SYNH) For Now

Investors are optimistic about Syneos Health (SYNH), given the strength in its Clinical Solutions business and notable partnership deals.

Syneos Health's (SYNH) New Buyout Boosts Clinical Solutions Arm

Syneos Health (SYNH) acquisition of StudyKIK strengthens the former's ability to provide technology and insight-driven solutions.

Syneos Health (SYNH) Enhances Clinical Trials With New Pact

Syneos Health (SYNH) recent partnership develops a more patient-centric travel experience, advances diversity and inclusion in clinical research.

Syneos Health (SYNH) Up 11.8% Since Last Earnings Report: Can It Continue?

Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Syneos Health (SYNH) Hits a 52-Week High: What's Driving It?

Strong performance by the Clinical Solutions and Commercial Solutions segments drove Syneos Health's (SYNH) top line.

Syneos Health (SYNH) Q2 Earnings Top Estimates, 2021 View Up

Syneos Health (SYNH) reported better-than-expected revenues for the second quarter of 2021 on strong segmental performance.

Syneos Health (SYNH) Surpasses Q2 Earnings and Revenue Estimates

Syneos Health (SYNH) delivered earnings and revenue surprises of 3.19% and 0.71%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Earnings Expected to Grow: Should You Buy?

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Syneos' (SYNH) New Patient Consortium to Drive Innovation

Syneos' (SYNH) Patient Voice Consortium incorporates patient perspective across wide range of communities to guide product development lifecycle.

Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up

Syneos Health (SYNH) registers sales uptick in its Clinical Solutions business on the back of favorable acquisition impacts and increased project start-up activities.

Syneos Health (SYNH) Tops Q1 Earnings and Revenue Estimates

Syneos Health (SYNH) delivered earnings and revenue surprises of 6.76% and 1.83%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Reports Next Week: Wall Street Expects Earnings Growth

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Reasons to Hold on to Syneos Health (SYNH) Stock For Now

Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery of its operating segments and strategic partnerships.